Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population

References

• Tavora F, Kutys R, Li L, Ripple M, Fowler D, Burke A. Adventitial lymphocytic inflammation in human coronary arteries with intimal atherosclerosis. Cardiovasc Pathol 2009. In press.
   Google Scholar
• Sattler A, Wagner U, Rossol M, Sieper J, Wu P, Krause A, Schmidt WA, Radmer S, Kohler S, Romagnani C, Thiel A. Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. Blood 2009;113:1948–56.
   PubMedGoogle Scholar
• Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998;161:3919–24.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–65.
   PubMed Web of Science ®Google Scholar
• Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B, Bonnefoy JY, Delneste Y. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren’s syndrome and systemic sclerosis. Clin Exp Immunol 2004;136:388–92.
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000;201:144–53.
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44:989–94.
   PubMed Web of Science ®Google Scholar
• Ip WK, Wong CK, Leung TF, Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int Arch Allergy Immunol 2005;137:45–52.
   PubMedGoogle Scholar
• Sakthivel P, Shively V, Kakoulidou M, Pearce W, Lefvert AK. The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J Intern Med 2007;261:399–407.
   PubMedGoogle Scholar
• Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 2002;16:865–73.
   PubMed Web of Science ®Google Scholar
• Hock BD, Starling GC, Patton WN, Salm N, Bond K, McArthur LT, McKenzie JL. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004;45:2111–8.
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015–8.
   PubMed Web of Science ®Google Scholar
• Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, Lefvert AK. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002;130: 224–32.
   PubMed Web of Science ®Google Scholar
• Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005;25: 2368–75.
   PubMed Web of Science ®Google Scholar
• Kakoulidou M, Wang X, Zhao X, Pirskanen R, Lefvert AK. Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis. J Neuroimmunol 2007; 185:150–61.
   PubMedGoogle Scholar
• Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005;51:1165–76.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB; Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486–91.
   PubMed Web of Science ®Google Scholar
• Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006;95:511–8.
   PubMed Web of Science ®Google Scholar
• Hamer M, Chida Y. Associations of very high C-reactive protein concentration with psychosocial and cardiovascular risk factors in an ageing population. Atherosclerosis 2009; 206:599–603.
   PubMed Web of Science ®Google Scholar
• Wong CK, Szeto CC, Chan MH, Leung CB, Li PK, Lam CW. Elevation of pro-inflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest 2007;36:47–57.
   PubMed Web of Science ®Google Scholar
• Guven A, Cetinkaya A, Aral M, Sokmen G, Buyukbese MA, Guven A, Koksal N. High-sensitivity C-reactive protein in patients with metabolic syndrome. Angiology 2006;57: 295–302.
   PubMed Web of Science ®Google Scholar
• Ozeren A, Aydin M, Tokac M, Demircan N, Unalacak M, Gurel A, Yazici M. Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Inflamm 2003;12:361–5.
   PubMed Web of Science ®Google Scholar
• Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2007;124:319–25.
   PubMedGoogle Scholar
• Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97: 714–21.
   PubMed Web of Science ®Google Scholar
• Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R, Bouthillier A, Becher B, Arbour N, David S, Stanimirovic D, Prat A. Activated leukocyte cell adhesion molecules promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008;9:137–45.
   PubMed Web of Science ®Google Scholar
• Turhan H, Erbay AR, Yasar AS, Aksoy Y, Bicer A, Yetkin G, Yetkin E. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia. Coron Artery Dis 2005;16:45–50.
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317–22.
   PubMed Web of Science ®Google Scholar
• Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006;24:131–41.
   PubMed Web of Science ®Google Scholar
• Van Vré EA, Bult H, Hoymans VY, Van Tendeloo VF, Vrints CJ, Bosmans JM. Human C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cell-mediated T-cell activation. Arterioscler Thromb Vasc Biol 2008;28:511–8.
   PubMedGoogle Scholar
• Castoldi G, Galimberti S, Riva C, Papagna R, Querci F, Casati M, Zerbini G, Caccianiga G, Ferrarese C, Baldoni M, Valsecchi MG, Stella A. Association between serum values of C-reactive protein and cytokine production in whole blood of type 2 diabetic patients. Clin Sci (Lond) 2007;113:103–8.
   PubMedGoogle Scholar
• Papadopoulou C, Corrigall V, Taylor PR, Poston RN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 2008;43:181–6.
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29: 3596–602.
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004;43:1261–6.
   PubMed Web of Science ®Google Scholar
• Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999;98:413–21.
   PubMed Web of Science ®Google Scholar
• Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004;39:687–99.
   PubMed Web of Science ®Google Scholar